AndreaBozzo/ceres-open-data-index huggingface dataset:
CDC Wastewater Data for Influenza A

This dataset provides a complete time history of Influenza A wastewater sample data and calculated metrics from US sampling locations. CDC’s National Wastewater Surveillance System (NWSS) includes data collected and reported by: • All data with a source designation of “State_Territory” were generated by state and local health departments are reported to CDC and supported with funding through the Epidemiology and Laboratory Capacity for the Prevention and Control of Emerging Infectious Diseases (ELC) Cooperative Agreement (https://www.cdc.gov/epidemiology-laboratory-capacity/php/our-work/index.html). • All data with a source designation of “CDC_Verily” were generated by CDC’s national wastewater testing contract (currently with Verily Life Sciences, LLC). • All data with a source designation of “WastewaterSCAN” were generated by WastewaterSCAN, a partnership between Stanford University, Emory University, and Verily. All results are understood to be based on inputs that are experimental in nature and are not intended to diagnose or treat any disease. The results are provided “as is” and without warranty of any kind. Stanford does not accept liability for any claim arising out of or in connection with the disclosure of these results. WastewaterSCAN indicates that by accessing or copying any part of the database, the user accepts the terms of Stanford’s license (CC BY-NC 4.0). These data are being made available to inform public health decision making. Anyone seeking to use the database for other purposes or for research is required to contact the WastewaterSCAN / SCAN team (email: wwscan_stanford_emory@lists.stanford.edu) and any use of the data should be cited appropriately (https://data.wastewaterscan.org/about/#18). Learn more at: https://www.cdc.gov/nwss/index.html. This dataset is updated weekly on Fridays.
CDC Wastewater Data for Measles

This dataset provides a complete time history of measles wastewater sample data and calculated metrics from US sampling locations. CDC’s National Wastewater Surveillance System (NWSS) includes data collected and reported by: • All data with a source designation of “State_Territory” were generated by state and local health departments are reported to CDC and supported with funding through the Epidemiology and Laboratory Capacity for the Prevention and Control of Emerging Infectious Diseases (ELC) Cooperative Agreement (https://www.cdc.gov/epidemiology-laboratory-capacity/php/our-work/index.html). • All data with a source designation of “CDC_Verily” were generated by CDC’s national wastewater testing contract (currently with Verily Life Sciences, LLC). • All data with a source designation of “WastewaterSCAN” were generated by WastewaterSCAN, a partnership between Stanford University, Emory University, and Verily. All results are understood to be based on inputs that are experimental in nature and are not intended to diagnose or treat any disease. The results are provided “as is” and without warranty of any kind. Stanford does not accept liability for any claim arising out of or in connection with the disclosure of these results. WastewaterSCAN indicates that by accessing or copying any part of the database, the user accepts the terms of Stanford’s license (CC BY-NC 4.0). These data are being made available to inform public health decision making. Anyone seeking to use the database for other purposes or for research is required to contact the WastewaterSCAN / SCAN team (email: wwscan_stanford_emory@lists.stanford.edu) and any use of the data should be cited appropriately (https://data.wastewaterscan.org/about/#18). Learn more at: https://www.cdc.gov/nwss/index.html. This dataset is updated weekly on Fridays.
CDC Wastewater Data for Mpox

This dataset provides a complete time history of monkeypox virus wastewater sample data and calculated metrics from US sampling locations. CDC’s National Wastewater Surveillance System (NWSS) includes data collected and reported by: • All data with a source designation of “State_Territory” were generated by state and local health departments are reported to CDC and supported with funding through the Epidemiology and Laboratory Capacity for the Prevention and Control of Emerging Infectious Diseases (ELC) Cooperative Agreement (https://www.cdc.gov/epidemiology-laboratory-capacity/php/our-work/index.html). • All data with a source designation of “CDC_Verily” were generated by CDC’s national wastewater testing contract (currently with Verily Life Sciences, LLC). • All data with a source designation of “WastewaterSCAN” were generated by WastewaterSCAN, a partnership between Stanford University, Emory University, and Verily. All results are understood to be based on inputs that are experimental in nature and are not intended to diagnose or treat any disease. The results are provided “as is” and without warranty of any kind. Stanford does not accept liability for any claim arising out of or in connection with the disclosure of these results. WastewaterSCAN indicates that by accessing or copying any part of the database, the user accepts the terms of Stanford’s license (CC BY-NC 4.0). These data are being made available to inform public health decision making. Anyone seeking to use the database for other purposes or for research is required to contact the WastewaterSCAN / SCAN team (email: wwscan_stanford_emory@lists.stanford.edu) and any use of the data should be cited appropriately (https://data.wastewaterscan.org/about/#18). Learn more at: https://www.cdc.gov/nwss/index.html. This dataset is updated weekly on Fridays.
CDC Wastewater Data for RSV

This dataset provides a complete time history of RSV wastewater sample data and calculated metrics from US sampling locations. CDC’s National Wastewater Surveillance System (NWSS) includes data collected and reported by: • All data with a source designation of “State_Territory” were generated by state and local health departments are reported to CDC and supported with funding through the Epidemiology and Laboratory Capacity for the Prevention and Control of Emerging Infectious Diseases (ELC) Cooperative Agreement (https://www.cdc.gov/epidemiology-laboratory-capacity/php/our-work/index.html). • All data with a source designation of “CDC_Verily” were generated by CDC’s national wastewater testing contract (currently with Verily Life Sciences, LLC). • All data with a source designation of “WastewaterSCAN” were generated by WastewaterSCAN, a partnership between Stanford University, Emory University, and Verily. All results are understood to be based on inputs that are experimental in nature and are not intended to diagnose or treat any disease. The results are provided “as is” and without warranty of any kind. Stanford does not accept liability for any claim arising out of or in connection with the disclosure of these results. WastewaterSCAN indicates that by accessing or copying any part of the database, the user accepts the terms of Stanford’s license (CC BY-NC 4.0). These data are being made available to inform public health decision making. Anyone seeking to use the database for other purposes or for research is required to contact the WastewaterSCAN / SCAN team (email: wwscan_stanford_emory@lists.stanford.edu) and any use of the data should be cited appropriately (https://data.wastewaterscan.org/about/#18). Learn more at: https://www.cdc.gov/nwss/index.html. This dataset is updated weekly on Fridays.
CDC Wastewater Data for SARS-CoV-2

This dataset provides a complete time history of SARS-CoV-2 wastewater sample data and calculated metrics from US sampling locations. CDC’s National Wastewater Surveillance System (NWSS) includes data collected and reported by: • All data with a source designation of “State_Territory” were generated by state and local health departments are reported to CDC and supported with funding through the Epidemiology and Laboratory Capacity for the Prevention and Control of Emerging Infectious Diseases (ELC) Cooperative Agreement (https://www.cdc.gov/epidemiology-laboratory-capacity/php/our-work/index.html). • All data with a source designation of “CDC_Verily” were generated by CDC’s national wastewater testing contract (currently with Verily Life Sciences, LLC). • All data with a source designation of “WastewaterSCAN” were generated by WastewaterSCAN, a partnership between Stanford University, Emory University, and Verily. All results are understood to be based on inputs that are experimental in nature and are not intended to diagnose or treat any disease. The results are provided “as is” and without warranty of any kind. Stanford does not accept liability for any claim arising out of or in connection with the disclosure of these results. WastewaterSCAN indicates that by accessing or copying any part of the database, the user accepts the terms of Stanford’s license (CC BY-NC 4.0). These data are being made available to inform public health decision making. Anyone seeking to use the database for other purposes or for research is required to contact the WastewaterSCAN / SCAN team (email: wwscan_stanford_emory@lists.stanford.edu) and any use of the data should be cited appropriately (https://data.wastewaterscan.org/about/#18). Learn more at: https://www.cdc.gov/nwss/index.html. This dataset is updated weekly on Fridays.
Census tracts with no Well Water Index (WWI) assigned

The WWI is a screening tool that uses nationally available datasets to summarize baseline characteristics about weather-related hazards and vulnerability at the census tract level for communities reliant on private wells. This dataset contains continental US census tracts for which no WWI was created due to less than 1 estimated person being on well water in the census tract. To visualize these data, please visit the Tracking Network at https://ephtracking.cdc.gov/DataExplorer/. For a lay description of these data, please visit https://ephtracking.cdc.gov/indicatorPages and for the scientific publication detailing these data please visit https://pubmed.ncbi.nlm.nih.gov/39510280/ The data for the nationally-normed WWI can be accessed here https://data.cdc.gov/dataset/Nationally-normed-WWI/fxwg-3udm/about_data. The data for the state-normed WWI can be accessed here https://data.cdc.gov/dataset/State-Normed-WWI/snkv-n8f6/about_data
Characteristics Associated with Successful Foodborne Outbreak Investigations, NEARS 2014 - 2016

This study examined relationships between foodborne outbreak investigation characteristics, such as the epidemiological methods used, and the success of the investigation, as determined by whether the investigation identified an outbreak agent (i.e., pathogen), food item, and contributing factor. This study used data from the Centers for Disease Control and Prevention’s (CDC) National Outbreak Reporting System (NORS) and National Environmental Assessment Reporting System (NEARS) to identify outbreak investigation characteristics associated with outbreak investigation success. We identified investigation characteristics that increase the probability of successful outbreak investigations: a robust epidemiology investigation method; a thorough environmental assessment, as measured by number of visits to complete the assessment; and the collection of clinical samples. This research highlights the importance of a comprehensive outbreak investigation, which includes epidemiology, environmental health, and laboratory personnel working together to solve the outbreak.
COVID-19 Vaccination Age and Sex Trends in the United States, National and Jurisdictional

This site provides data for select demographic characteristics (age, sex, and age by sex) of people receiving COVID-19 vaccinations in the United States at the national and jurisdictional levels. For national race/ethnicity data, please visit [COVID-19 Vaccination Demographics in the United States,National]. For jurisdictional race/ethnicity data, please visit the relevant health department website if available. Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.
Commercial Medical Insurance (MSCANCC) - Vision and Eye Health Surveillance

2016, 2020, 2021, 2022, 2023. This dataset is a de-identified summary table of prevalence rates for vision and eye health data indicators from the 2016 MarketScan® Commercial Claims and Encounters Data (CCAE) is produced by Truven Health Analytics, a division of IBM Watson Health. The CCEA data contain a convenience sample of insurance claims information from person with employer-sponsored insurance and their dependents, including 43.6 million person years of data. Prevalence estimates are stratified by all available combinations of age group, sex, and state. Detailed information on VEHSS MarketScan analyses can be found on the VEHSS MarketScan webpage (cdc.gov/visionhealth/vehss/data/claims/marketscan.html). Information on available Medicare claims data can be found on the IBM MarketScan website (https://marketscan.truvenhealth.com). The VEHSS MarketScan summary dataset was last updated 2025.
Community Water Fluoridation – State and County Level Statistics

State, 2016 –2020; County, 2020. The report includes both state and county level water fluoridation data generated from the Water Fluoridation Reporting System (WFRS). State level statistics include data from the biennial report originally published at https://www.cdc.gov/fluoridation/statistics/reference_stats.htm. State and county data include percentage of people, number of people, and number of water systems receiving fluoridated water. County level data is not displayed for all states. Participation in sharing county level data is voluntary and state programs determine if data will be shown.
Conditions Contributing to COVID-19 Deaths, by State and Age, Provisional 2020-2023

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov. This dataset shows health conditions and contributing causes mentioned in conjunction with deaths involving coronavirus disease 2019 (COVID-19) by age group and jurisdiction of occurrence. 2022 and 2023 data are provisional. Estimates for 2020 and 2021 are based on final data.
county-level ASD prevalence estimates

This table provides county-level prevalence for 2018 for seven US states using linked statewide health and education data. For full methods see: Shaw KA, Williams S, Hughes MM, Warren Z, Bakian AV, Durkin MS, et al. Statewide county-level autism spectrum disorder prevalence estimates — seven U.S. states, 2018. Annals of Epidemiology. 2023 Jan 18; Available from: https://www.sciencedirect.com/science/article/pii/S1047279723000182
COVID-19 Booster Dose Eligibility in the United States

This site provides historical data related to COVID-19 booster dose eligibility presented on two CDC COVID Data Tracker sites: [Vaccinations in the US] and [Vaccination Equity]. Data are updated weekly on Thursdays. Some COVID-19 vaccine recipients are [eligible to receive booster doses], and criteria for booster eligibility may change over time. Data and footnotes will be updated to align with the current recommendations. CDC counts people as having “received a booster dose” if they are fully vaccinated and received another dose of any COVID-19 vaccine on or after August 13, 2021. This does not distinguish whether the recipient is [immunocompromised and received an additional dose] Data Limitations: * The booster eligibility metric excludes fully vaccinated recipients who have an “Other” primary series vaccine type. * Booster eligibility counts and percentages exclude vaccine administrations reported by Texas as the primary series cannot be linked to booster dose in the aggregate data submitted by Texas. Footnotes: CDC counts people as being “[eligible to get a booster dose]<
COVID-19 Coverage Assistance Fund: Claims Reimbursement to Health Care Providers and Facilities for Services to the Underinsured

The COVID-19 Coverage Assistance Fund provides reimbursements on a rolling basis directly to eligible health care entities for costs associated with administering COVID-19 vaccines to underinsured individuals, who are defined for this purpose as having a health plan that either does not include COVID-19 vaccine administration as a covered benefit or covers COVID-19 vaccine administration but with cost-sharing. The program funding information is as follows: The Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136), appropriated $100 billion to reimburse eligible health care providers for health care related expenses or lost revenues that are attributable to coronavirus. The Paycheck Protection Program and Health Care Enhancement Act or PPPHCEA (P.L. 116-139) appropriated an additional $75 billion for relief funds, and the Coronavirus Response and Relief Supplemental Appropriations (CRRSA) Act appropriated an additional $3 billion. HRSA established the Provider Relief Fund (PRF) to administer payments to eligible providers. A portion of the PRF funds are being used to provide reimbursement to providers for administering Food and Drug Administration (FDA) authorized COVID-19 vaccines under an Emergency Use Authorization (EUA) or FDA-licensed COVID-19 vaccines under a Biologics License Application (BLA) to underinsured individuals. To learn more about the program, visit: https://www.hrsa.gov/covid19-coverage-assistance This dataset represents the list of health care entities who have agreed to the Terms and Conditions and received claims reimbursement for costs associated with administering COVID-19 vaccines to underinsured individuals. For Provider Relief Fund Data - https://data.cdc.gov/Administrative/HHS-Provider-Relief-Fund/kh8y-3es6
COVID-19 Hospital Data from the National Hospital Care Survey

The National Hospital Care Survey (NHCS) collects data on patient care in hospital-based settings to describe patterns of health care delivery and utilization in the United States. Settings currently include inpatient and emergency departments (ED). Additionally, the NHCS contributes data that may inform public health emergencies as the survey is designed to capture emerging diseases and viruses that require hospitalizations, including COVID-19 encounters. The 2020 - 2023 NHCS are not yet fully operational so it is important to note that these data are not nationally representative. The data are from 26 hospitals submitting inpatient and 26 hospitals submitting ED Uniform Bill (UB)-04 administrative claims from March 18, 2020-December 26, 2023. Even though the data are not nationally representative, they can provide insight on the impact of COVID-19 on various types of hospitals throughout the country. This information is not available in other hospital reporting systems. The NHCS data from these hospitals can show results by a combination of indicators related to COVID-19, such as length of inpatient stay, in-hospital mortality, comorbidities, and intubation or ventilator use. NHCS data allow for reporting on patient conditions and treatments within the hospital over time.
COVID-19 Primary Series Completion, Booster Dose Eligibility, and Booster Dose Receipt by Age, United States

This site provides historical data beginning June 22, 2022, for the visualization presented on [COVID-19 Data Tracker’s “Vaccinations in the United States”] site titled “Primary Series Completion, Booster Dose Eligibility, and Booster Dose Receipt by Age, United States”. Fully Vaccinated / Completed Primary Series: * For surveillance purposes, COVID Data Tracker counts people as being "fully vaccinated" or as having "completed a primary series" if they received two doses on different days (regardless of time interval) of the two-dose mRNA series or received one dose of a single-dose vaccine. When the vaccine manufacturer is not reported, the recipient is considered fully vaccinated with two doses. First Booster Dose: * For surveillance purposes, the count and percentage of people who received a first booster dose includes anyone who is fully vaccinated and has received another dose of COVID-19 vaccine since August 13, 2021. This includes people who received a first booster dose and people who received an additional primary series dose as this metric does not distinguish if the recipient is [ immunocompromised and received an additional dose]. * First booster dose eligibility: * CDC counts people as being " [eligible for a first booster dose]" if it has been at least 5 months since completion of a Pfizer-BioNTech or Moderna primary series or at least 2 months since receipt of a Janssen (Johnson & Johnson) singe-dose vaccine. Second Booster Dose: * For surveillance purposes, the count and percentage of people who received a second booster dose includes anyone who is fully vaccinated and has received two subsequent doses of COVID-19 vaccine since August 13, 2021. This includes people who received two booster doses and people who received one additional dose and one booster dose. * The count of people who received a second booster dose and the percentage of people with a first booster who received a second booster dose does not account for whether a person is [immunocompromised or time interval since first booster dose]. * Second booster dose eligibility: * CDC counts people as being "[eligible for a second booster dose]" if it has been at least 4 months since receiving a first booster dose. * Limitations to counting people with a second booster dose: * Due to the aggregate vaccination record reporting method used by Idaho for its residents under the age of 18 years and by Texas for all its residents, CDC counts all 4th doses received by these populations as a second booster dose. This includes immunocompromised individuals who received a three-dose primary series and only one booster dose. This limitation may lead to an undercount of people who received the single-dose J&J/Janssen vaccine as their primary series and two booster doses. Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.
COVID-19 State, Tribal, Local, and Territorial Funding

The U.S. government has taken unprecedented action to address the public health threat posed by this new coronavirus. To accelerate response efforts, CDC received supplemental funds through five congressional acts: the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; Coronavirus Aid, Relief, and Economic Security Act; Paycheck Protection Program and Health Care Enhancement Act; Coronavirus Response and Relief Supplemental Appropriations Act, 2021; and American Rescue Plan Act of 2021. CDC is actively funding state, tribal, local, and territorial public health organizations to meet the challenges of this fast-moving public health threat.
COVID-19 Updated Vaccines Distributed

This site provides historical data beginning June 14, 2023, for the visualization presented on [COVID-19 Data Tracker’s “Vaccinations in the United States" ] site titled “US COVID-19 Vaccine Doses Delivered by Vaccine Type” Definition for Distributed: Cumulative number of COVID-19 updated vaccine doses distributed in the United States. CDC is no longer reporting metrics for Johnson & Johnson, and the original Pfizer and Moderna vaccines. Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.